



## **Checkmate Pharmaceuticals to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting**

*Checkmate's data will be highlighted in an oral presentation at the Clinical Trials Plenary Session*

**CAMBRIDGE, Mass., March 28, 2018** – [Checkmate Pharmaceuticals](#) (Checkmate), a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, today announced that it will present data at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago from April 14 – April 18. Data on Checkmate's Phase 1b trial in subjects with advanced melanoma will be presented in an oral presentation in the Clinical Trials Plenary Session CTPL04 - Novel Immuno-oncology Strategies.

### **Oral Presentation Details:**

**Title:** Intratumoral Toll-Like Receptor 9 (TLR9) Agonist, CMP-001, In Combination With Pembrolizumab Can Reverse Resistance To PD-1 Inhibition In A Phase 1b Trial In Subjects With Advanced Melanoma

**Abstract No:** 10610

**Presentation Number:** CT144

**Date/Time:** April 17, 2018; 10:30 AM

**Location:** North Hall C, McCormick Place North (Level 1)

### **About Checkmate**

Checkmate Pharmaceuticals is a clinical stage company leveraging its expertise in the field of CpG oligonucleotides (TLR9 agonists) to specifically activate the innate arm of the immune system to stimulate a systemic antitumor cytolytic T cell (CTL) response. In combination with checkpoint inhibition, which blocks the tumor's ability to mute the immune response, Checkmate's TLR9 agonist triggers a powerful CTL response to recognize and ultimately destroy tumor cells.

Checkmate is a privately held company headquartered in Cambridge, MA.

Information regarding Checkmate is available at [www.checkmatepharma.com](http://www.checkmatepharma.com).

**###**

### **CONTACTS:**

#### **Company Contact:**

Checkmate Pharmaceuticals, Inc.

Art Krieg, MD, CEO

[akrieg@checkmatepharma.com](mailto:akrieg@checkmatepharma.com)

**Media Contact:**

MacDougall Biomedical Communications

Karen Sharma

781-235-3060

[ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)